Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Arrault, X.
Right arrow Articles by Touati, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arrault, X.
Right arrow Articles by Touati, E.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Mutagenesis, Vol. 17, No. 4, 353-359, July 2002
© 2002 UK Environmental Mutagen Society/Oxford University Press

Comparison of kinetics of induction of DNA adducts and gene mutations by a nitrofuran compound, 7-methoxy-2-nitronaphtho[2,1-b]furan (R7000), in the caecum and small intestine of Big BlueTM mice

Xavier Arrault, Valérie Michel, Philippe Quillardet, Maurice Hofnung{dagger} and Eliette Touati1

Unité de Programmation Moléculaire et de Toxicologie Génétique, CNRS Ura 1444, Institut Pasteur, 25 Rue du Dr Roux, 75724 Paris cedex 15, France

In previous experiments, i.p. injection of the 5 nitronaphthofuran derivative 7-methoxy-2-nitronaphtho[2,1-b]furan (R7000) to lacI transgenic Big BlueTM mice led to an increase in the mutant frequency (MF), especially in the caecum and the small intestine. In the present work, the in vivo genotoxicity of R7000 in these two target organs was further investigated. Big BlueTM mice were treated with a single daily i.p. injection of R7000 of 0.05–0.5 mg/day for five consecutive days and killed 28 days later. These treatments led to significant increases in MF of 1.8-, 3- and 5.4-fold at 0.1, 0.2 and 0.5 mg/day R7000, respectively, in the small intestine. In the caecum, a mutagenic effect, of 4.5-fold, was only observed at the highest dose. DNA adduct formation and MFs resulting from R7000 were also analysed in parallel at various times after the last injection. R7000 led to 14 and seven different nucleotide modifications in the caecum and small intestine, respectively. Three hours after the final injection the level of induced DNA adducts was 10 times higher in the caecum than in the small intestine. From 3 h to 5 days after the final injection, 93 and 58% of DNA adducts disappeared in the caecum and small intestine, respectively. The resulting MF values were similar when comparing the two organs. Analysis of the R7000-induced mutation spectrum in the caecum showed that single G:C and large, >=3 bp deletions and GC->CG transversions were the first induced mutations at the end of the treatment. Fifteen days later, the R7000 mutation specificity characteristics already reported in Escherichia coli and in the small intestine of Big BlueTM mice were evident in the caecum, with the two major events being GC->TA transversions and deletions of one G:C base pair. In both organs, a relationship between the decrease in R7000–DNA adducts and induction of MF was evident. However, the efficiency of this compound in damaging DNA was not correlated with the capacity of DNA lesions to lead to mutations. Some discrepancies in the R7000 genotoxic effects between the two organs were observed, which may be attributable to differences in the metabolic activation pathway of the compound, as well as to DNA repair proficiency in each tissue.

1 To whom correspondence should be addressed. Tel: +33 1 45 68 32 88; Fax: +33 1 45 68 88 34; Email: etouati{at}pasteur.fr

{dagger} This paper is dedicated to the memory of Maurice Hofnung who died during this work


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CarcinogenesisHome page
L. E. Sandercock, J. N. Hahn, L. Li, H.A. Luchman, J. L. Giesbrecht, L. A. Peterson, and F. R. Jirik
Mgmt deficiency alters the in vivo mutational spectrum of tissues exposed to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)
Carcinogenesis, April 1, 2008; 29(4): 866 - 874.
[Abstract] [Full Text] [PDF]


Home page
MutagenesisHome page
P. Quillardet, X. Arrault, V. Michel, and E. Touati
Organ-targeted mutagenicity of nitrofurantoin in Big Blue transgenic mice
Mutagenesis, September 1, 2006; 21(5): 305 - 311.
[Abstract] [Full Text] [PDF]


Home page
GeneticsHome page
Y.-X. Fu and H. Huai
Estimating Mutation Rate: How to Count Mutations?
Genetics, June 1, 2003; 164(2): 797 - 805.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.